Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
OCTREOTIDE ACETATE, Paltusotine tablets
Lacuna Pharma Pty Ltd
Carcinoid Syndrome
1 trial -
ONO-4578, ONO-4578, BEVACIZUMAB, ONO-4578, CALCIUM FOLINATE, OXALIPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., FLUOROURACIL
Lacuna Pharma Pty Ltd
PD-L1 positive advanced colorectal cancer
1 trial -
Ocaliva 5 mg film-coated tablets
Lacuna Pharma Pty Ltd
Primary biliary cholangitis
1 trial -
Odronextamab, Odronextamab, Odronextamab
Lacuna Pharma Pty Ltd
B-cell non-Hodgkin lymphoma (NHL)
1 trial -
Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (recombinant human Annexin A5 protein) in the treatment of patients with either Diabetic Retinopathy or recent onset Retinal Vein Occlusion
Lacuna Pharma Pty Ltd
Diabetic Retinopathy, Retinal Vein Occlusion
1 trial -
PEMBROLIZUMAB, PM54
Lacuna Pharma Pty Ltd
Advanced malignancies
1 trial -
PLACEBO, BELTAVAC polymerized grass mix, BELTAVAC polymerized grass mix, -
Lacuna Pharma Pty Ltd
allergic rhinoconjunctivitis caused due to exposure to pollen grasses
1 trial -
PLACEBO, BELTAVAC polymerized grass mix, BELTAVAC polymerized grass mix, BELTAVAC polymerized grass mix, -
Lacuna Pharma Pty Ltd
Allergic rhinoconjunctivitis caused due to exposure to pollen grasses
1 trial -
PM14, IRINOTECAN
Lacuna Pharma Pty Ltd
Patients with Selected Advanced Solid Tumors
1 trial -
Paltusotine tablets, Paltusotine tablets
Lacuna Pharma Pty Ltd
Acromegaly
1 trial -
Pariglasgene brecaparvovec
Lacuna Pharma Pty Ltd
Glycogen storage disease type Ia
1 trial -
Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, Carboplatino Aurovitas 10 mg/ml concentrado para solución para perfusión EFG, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Glenmark 10 mg/ml solución para perfusión, Carboplatino Hikma 10 mg/ml soluzione per infusione, OMTX705, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Carboplatino Teva 10 mg/ml Concentrado para solución para perfusión, Carboplatino Accord 10 mg/ml concentrado para
Lacuna Pharma Pty Ltd
Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
1 trial -
Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion, Paclitaxel AqVida 6 mg/ml concentrate for solution for infusion, REGN7075, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., LIBTAYO 350 mg concentrate for solution for infusion., Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Lacuna Pharma Pty Ltd
Non-Small Cell Lung Cancer
1 trial -
Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients with Advanced Solid Tumors
Lacuna Pharma Pty Ltd
advanced solid tumors
1 trial -
Phase I Study of PM534 Administered to Patients with Advanced Solid Tumors
Lacuna Pharma Pty Ltd
Advanced Solid Tumors
1 trial -
Phase I Study of PM534 to Patients with Advanced Solid Tumors
Lacuna Pharma Pty Ltd
Advances solid tumors
1 trial -
Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors
Lacuna Pharma Pty Ltd
Advanced Solid Tumors
1 trial -
Pimavanserin Capsules 10 mg, Pimavanserin 34 mg Capsule, Pimavanserin 20 mg Capsule
Lacuna Pharma Pty Ltd
Irritability associated with autistic disorder in children and adolescents with ASD
1 trial -
Pirfenidone Solution for Inhalation
Lacuna Pharma Pty Ltd
Progressive pulmonary fibrosis [PPF] Idiopathic pulmonary fibrosis [IPF]
1 trial -
Pirfenidone Solution for Inhalation
Lacuna Pharma Pty Ltd
Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF)
1 trial -
Pirfenidone Solution for Inhalation, Pirfenidone Solution for Inhalation, Placebo for AP01
Lacuna Pharma Pty Ltd
Progressive Pulmonary Fibrosis
1 trial -
Piromelatine (Neu-P11)
Lacuna Pharma Pty Ltd
idiopathic (isolated) Rapid Eye Movement Behavior Disorder
1 trial -
Placebo
Lacuna Pharma Pty Ltd
Severe Alcohol-Associated Hepatitis
1 trial -
Placebo 100 mg tablet, NMD670, Placebo 300 mg tablet, NMD670
Lacuna Pharma Pty Ltd
Type 3 spinal muscular atrophy
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources